Sensei Biotherapeutics (NASDAQ:FTH) Upgraded by Wall Street Zen to Hold Rating

Key Points

• Wall Street Zen upgraded Sensei Biotherapeutics from “sell” to “hold,” while the broader analyst consensus remains “Moderate Buy” with an average price target of $55.
• Shares opened at $32, down 0.3%, with a market capitalization of about $826.9 million. The company reported quarterly EPS of -$2.84, beating the consensus estimate of -$5.04.
• Institutional investors own 10.5% of the company, while insiders own 7%; recent activity included a major shareholder sale and CEO purchase, alongside new stakes from Vivo Capital and Stempoint Capital.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

Other research analysts also recently issued research reports about the stock. BTIG Research reaffirmed a "buy" rating and set a $55.00 price objective on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. Weiss Ratings started coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They issued a "sell (d-)" rating on the stock. Citizens Jmp started coverage on shares of Sensei Biotherapeutics in a report on Monday, July 20th. They issued an "outperform" rating and a $51.00 target price for the company. Oppenheimer initiated coverage on shares of Sensei Biotherapeutics in a research report on Tuesday, July 28th. They set an "outperform" rating and a $60.00 price target for the company. Finally, JonesTrading began coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, August 4th. They set a "buy" rating and a $55.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $55.00.

Sensei Biotherapeutics Trading Down 0.3%

Shares of Sensei Biotherapeutics stock opened at $32.00 on Friday. Sensei Biotherapeutics has a fifty-two week low of $7.45 and a fifty-two week high of $37.90. The stock has a market cap of $826.88 million, a price-to-earnings ratio of -0.23 and a beta of -0.25. The business's fifty day simple moving average is $27.27.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.04) by $2.20. On average, analysts forecast that Sensei Biotherapeutics will post -13.18 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder James Peyer sold 25,000 shares of the company's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the completion of the sale, the insider directly owned 130,142 shares of the company's stock, valued at approximately $2,605,442.84. This represents a 16.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Anand Kiran Parikh purchased 2,806 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was bought at an average price of $19.76 per share, with a total value of $55,446.56. Following the completion of the acquisition, the chief executive officer owned 764,234 shares in the company, valued at $15,101,263.84. This represents a 0.37% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have acquired 49,494 shares of company stock valued at $1,188,822. Company insiders own 7.00% of the company's stock.

Institutional Investors Weigh In On Sensei Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC raised its holdings in shares of Sensei Biotherapeutics by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company's stock valued at $123,000 after buying an additional 1,100 shares during the period. Stempoint Capital LP purchased a new position in Sensei Biotherapeutics in the 1st quarter worth approximately $4,188,000. Bank of America Corp DE boosted its holdings in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock worth $1,041,000 after acquiring an additional 32,719 shares during the period. Vivo Capital LLC acquired a new stake in Sensei Biotherapeutics in the first quarter valued at approximately $22,758,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Sensei Biotherapeutics in the second quarter valued at approximately $3,610,000. Hedge funds and other institutional investors own 10.50% of the company's stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source